Sickle cell disease (SCD) is a group of related yet genetically complex hemoglobinopathies. Universal newborn screening (NBS) for SCD is performed in the United States and many other nations. Classical, protein-based laboratory methods are often adequate for the diagnosis of SCD but have specific limitations in the context of NBS. A particular challenge is the differentiation of sickle cell anemia (SCA) from the benign condition, compound heterozygosity for HbS and gene-deletion hereditary persistence of fetal hemoglobin (HbS/HPFH). We describe a sequential cohort of 44 newborns identified over 4.5 years who had molecular genetic testing incorporated into NBS for presumed SCA (an “FS” pattern). The final diagnosis was something other than SCA in six newborns (12%). Three (7%) had HbS/HPFH. All had a final, correct diagnosis at the time of their first scheduled clinic visit in our center (median 8 weeks of age). None received initial counseling for an incorrect diagnosis. In summary, genetic testing as a component of NBS for SCD is necessary to provide correct genetic counseling and education for all newborns' families at their first visit to a sickle cell center. Genetic testing also permits the use of early, pre-symptomatic hydroxyurea therapy by preventing infants with HbS/HPFH from receiving unnecessary therapy. We argue that genetic testing should be incorporated into contemporary NBS for SCD.
Hemoglobin separation techniques are the most commonly used laboratory methods in newborn screening and confirmatory testing programs for hemoglobinopathies. However, such protein-based testing cannot accurately detect several hemoglobinopathies in newborns, especially when β-thalassemia mutations are involved. Here, we describe a consecutive cohort of newborns who were identified by newborn screening to have a likely diagnosis of sickle-β+-thalassemia (having an “FSA” pattern) who were determined to have sickle cell traits by confirmatory and genetic testing. We illustrate the clinical utility of genetic testing to make a correct and timely diagnosis in the setting of newborn screening for hemoglobinopathies.
The 2020 Hemoglobinopathy Counselor Training Course was scheduled for 15-16 April 2020 in Cincinnati, Ohio. Organised by the Cincinnati Comprehensive Sickle Cell Center, this two-day course has taken place in-person for over 15 years. However, due to COVID-19 concerns and recommendations for large gatherings, 1 the course was transitioned into an online format. Impact on knowledge 2 | WHAT WA S TRIED? We created an hour-long conference titled 'Seattle VICE: Virtual Interactive Case-based Education'. We used an Internet-based platform with screen-sharing and virtual breakout group capabilities (Zoom™), and a text-based audience response system (Poll everywhere™). We modelled the conference after the New England Journal of Medicine 'Clinical Problem Solving' series and the popular medical podcast Clinical Problem Solvers (clinicalproblemsolving.com). We chose this format for several reasons: it mirrors how clinical reasoning occurs in real-world settings, it effectively elicits trainees' clinical reasoning, and it allows participants to learn practical approaches to common clinical scenarios through collegial discussion. Cases are presented to volunteers in
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.